Report
Overview
Together,
the four major cancer markets, which include colorectal,
prostate, lung and breast cancer were valued at
well over $16 billion in 2005, which was an increase
of 14 percent in value since 2004. Driving this
growth are innovative new products, line extensions
for existing products, and the coming of age of
the biotech industry.
Arrowhead
Publishers’ report entitled Cancer Therapeutics
2006: Market Dynamics and R&D Trends examines
these four major cancer markets in light of newly
emerging therapeutics, shifting market shares and
line extensions for major products on the market.
Features
of this Report:
-
market analysis by class, cancer type, product,
company, and geographic region;
-
sales
data from 2000 through Sept 2005 as well as full-year
2005 estimates;
-
profiles
of leading products in the four major cancer markets
and analysis of their market impact;
-
presentation
and analysis of clinical data underscoring success
of key therapies;
-
market
share
data for leading companies and products in the
field;
-
SWOT
analysis for key products in each market;
-
profiles
of key emerging therapies and clinical data supporting
development;
-
financial
forecasts for the four major cancer markets;
-
133
tables/graphs/diagrams illustrating historical
sales data, growth rates and market share by product,
class, therapeutic category, and company, company
portfolios, pipelines, clinical efficacy data,
as well as epidemiologic data.
Additionally,
Cancer Therapeutics 2006 offers readers a critical
examination of emerging and pipeline products in
colorectal, prostate, lung, and breast cancer. Pipeline
products with the greatest potential are assessed
for their clinical efficacy and possible market
impact. Briefs are provided for companies that are
either firmly entrenched in one of these four cancer
markets or are developing groundbreaking new drugs
that are being designed to treat not only one of
the leading four cancers, but other cancers as well.
|
